Prevalence of large vessel vasculitis in ANCA-associated vasculitis: a retrospective cohort study.
ANCA-associated vasculitis
Antineutrophil cytoplasmic antibodies
Aortitis
Eosinophilic granulomatosis with polyangiitis
Granulomatosis with polyangiitis
Large vessel vasculitis
Microscopic polyangiitis
Temporal arteritis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
02
06
2021
accepted:
11
09
2021
pubmed:
25
9
2021
medline:
21
1
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
ANCA-associated vasculitis (AAV) in general involves small blood vessels and includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA). Although reported in a few studies, the prevalence of large vessel vasculitis (LVV) in patients with AAV remains to be further explored. The goal of the present study was to assess the prevalence of LVV in a cohort of patients with AAV and to characterize this population. We conducted a ten-year retrospective study of a single-center cohort of AAV, including 101 patients with GPA (n = 58), EGPA (n = 28), MPA (n = 15), and compared the groups with or without associated LVV. LVV was diagnosed in five patients, two with aortitis and three with temporal arteritis, corresponding to a total prevalence of 5.0% [95% CI 1.6-11.2%]. This value was significantly higher than the estimated prevalence of LVV in the normal Swiss population (OR 234.9 95% CI 91.18-605.2, p < 0.001). All five patients had GPA, whereas no cases with EGPA or MPA were identified. Anti-PR3 antibodies were detected in four out of five patients, anti-MPO in one patient. Since LVV can occur in a significant proportion of patients with GPA, evaluation for LVV may be considered systematically in the diagnostic workup of AAV.
Identifiants
pubmed: 34559277
doi: 10.1007/s00296-021-04993-2
pii: 10.1007/s00296-021-04993-2
pmc: PMC8550277
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2147-2156Informations de copyright
© 2021. The Author(s).
Références
J Neurol. 2013 Jun;260(6):1661-3
pubmed: 23579235
Can J Ophthalmol. 2016 Jun;51(3):e108-9
pubmed: 27316282
Eur Respir J. 1994 Dec;7(12):2252-4
pubmed: 7713213
Arthritis Rheum. 1991 Feb;34(2):220-3
pubmed: 1994920
Ann Med Interne (Paris). 1992;143(7):429-32
pubmed: 1300861
J Neurol Sci. 2007 May 15;256(1-2):81-3
pubmed: 17379246
Intern Med. 2011;50(9):1033-7
pubmed: 21532228
BMJ Case Rep. 2017 Apr 21;2017:
pubmed: 28432167
Rheumatol Int. 2019 Nov;39(11):1983-1988
pubmed: 31222438
Am J Med. 2003 Apr 15;114(6):454-62
pubmed: 12727578
Clin Rheumatol. 2004 Apr;23(2):152-9
pubmed: 15045631
J Rheumatol. 1984 Oct;11(5):707-9
pubmed: 6512795
Am J Med. 1986 Jul;81(1):79-85
pubmed: 2873744
Mayo Clin Proc. 1993 Feb;68(2):115-21
pubmed: 8423690
Can J Ophthalmol. 2013 Feb;48(1):e6-8
pubmed: 23419311
Arthritis Rheum. 1990 Aug;33(8):1094-100
pubmed: 2202307
Neurology. 1991 Oct;41(10):1694-5
pubmed: 1922825
J Rheumatol. 2003 Oct;30(10):2165-9
pubmed: 14528512
Nat Rev Rheumatol. 2017 Nov;13(11):683-692
pubmed: 28905856
Arthritis Rheumatol. 2021 Feb;73(2):286-294
pubmed: 32951354
Arthritis Rheum. 1990 Aug;33(8):1122-8
pubmed: 2202311
Rev Med Interne. 2008 Oct;29(10):780-4
pubmed: 18372083
BMC Pulm Med. 2019 Jul 8;19(1):122
pubmed: 31286925
Rev Med Interne. 2008 Oct;29(10):830-1
pubmed: 18375020
Mod Rheumatol. 2012 Nov;22(6):934-8
pubmed: 22354635
Am J Med. 1984 Jul;77(1):135-40
pubmed: 6741975
Am J Case Rep. 2018 Jun 06;19:651-655
pubmed: 29872033
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Rheumatology (Oxford). 2000 Dec;39(12):1396-402
pubmed: 11136884
BMJ Case Rep. 2019 Jan 28;12(1):
pubmed: 30696638
Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(3):154-61
pubmed: 21720104